Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

PURPOSE: Diffuse large B-cell lymphoma (DLBCL) is curable in 60% of patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). MYC translocations, with or without BCL2 translocations, have been associated with inferior survival in DLBCL. We investigated...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Johnson, Nathalie A., Slack, Graham W., Savage, Kerry J., Connors, Joseph M., Ben-Neriah, Susana, Rogic, Sanja, Scott, David W., Tan, King L., Steidl, Christian, Sehn, Laurie H., Chan, Wing C., Iqbal, Javeed, Meyer, Paul N., Lenz, Georg, Wright, George, Rimsza, Lisa M., Valentino, Carlo, Brunhoeber, Patrick, Grogan, Thomas M., Braziel, Rita M., Cook, James R., Tubbs, Raymond R., Weisenburger, Dennis D., Campo, Elias, Rosenwald, Andreas, Ott, German, Delabie, Jan, Holcroft, Christina, Jaffe, Elaine S., Staudt, Louis M., Gascoyne, Randy D.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Clinical Oncology 2012
Assuntos:
ORIGINAL REPORTS
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3454768/
https://ncbi.nlm.nih.gov/pubmed/22851565
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.41.0985
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares